NETEC Resource Library

Ebola: characterization, history and cutaneous manifestations/ Ébola: caracterización, historia y manifestaciones cutáneas; lo que debemos saber

Contenu

Click for External Resource*


Click to read full article*


*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.


Files for Download

Ebola: characterization, history and cutaneous manifestationsart10.pdf

Item Type

Publication

Terms of Use

By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.

Voir les documents

Was this resource helpful?


Titre

Ebola: characterization, history and cutaneous manifestations/ Ébola: caracterización, historia y manifestaciones cutáneas; lo que debemos saber

Description

Ebola virus (EV) is one of the most virulent human pathogens. Fruits bats are its natural reservoir, the transmission to humans is across wild animals (especially primates) and the propagation in human populations is through bodily fluid contact.

Date

2015-11-01

Citer ce document

M. Kolbach, J. E. Carrasco-Zuber, and V. Vial-Letelier. "[Ebola: Characterization, History and Cutaneous Manifestations]." Rev Med Chil 143, no. 11 (Nov 2015): 1444-8.

Résumé

Ebola virus (EV) is one of the most virulent human pathogens. Fruits bats are its natural reservoir, the transmission to humans is across wild animals (especially primates) and the propagation in human populations is through bodily fluid contact. The actual outbreak started in December 2013 and crossed continental borders. Up to now, there are 17,145 suspected and confirmed cases with 6,070 deaths, resulting a total case fatality rate of 35%. Clinical manifestations can be divided in 3 phases. In phase I, symptoms are similar to flu, which may appear in a range of 2 to 21 days. In phase II which occurs in over 50% of cases, visceral symptoms and mucocutaneous manifestations appear within 4 and 5 days of the onset of symptoms. The main symptoms are a macular or maculopapular non-pruritic rash, desquamation and mucosal involvement of eyes, mouth and pharynx. In phase III, recovery or death occurs. The diagnosis is made on clinical grounds, epidemiological suspicion and a positive polymerase chain reaction (PCR) test. The treatment is supportive. If there is a suspected case, it should be notified immediately and all relevant safety measures should be instituted.

Accessibilité

Free online, CC-BY